{"id":"abo1105","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ABO1105 works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell growth and proliferation. This inhibition can lead to anti-tumor effects. ABO1105 has shown promise in preclinical studies as a potential treatment for various cancers.","oneSentence":"ABO1105 is a small molecule that targets the PI3K/AKT/mTOR pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:19.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07289503","phase":"PHASE1","title":"Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-05-27","conditions":"Respiratory Syncytial Virus","enrollment":96},{"nctId":"NCT07289542","phase":"PHASE2","title":"Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-09-15","conditions":"Respiratory Syncytial Virus","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABO1105","genericName":"ABO1105","companyName":"Suzhou Abogen Biosciences Co., Ltd.","companyId":"suzhou-abogen-biosciences-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ABO1105 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}